Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19

Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China


  • The total deal value is $362M and under this agreement, Samsung is expected to commence its manufacturing till Oct in Plant 3, with expected commercialization in early 2021. Additionally, the companies will continue to negotiate terms in agreement with expected finalization till Jul 31, 2020
  • The agreement follows the Vir’s manufacturing collaboration with WuXi Biologics and its letter of intent with Biogen. The focus of the collaboration is to perform large scale manufacturing services for Vir’s SARS-CoV-2 mAb program
  • Vir’s VIR-7831 and VIR-7832 candidates have demonstrated affinity towards SARS-CoV-2 spike protein also have potency to neutralize SARS-CoV-2 in live-virus cellular assays. Additionally, Vir plans to initiate P-II with three to five months

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Samsung